- Open Access
Inflammatory stress exacerbates ectopic lipid deposition in C57BL/6J mice
Lipids in Health and Diseasevolume 10, Article number: 110 (2011)
Chronic systemic inflammation and abnormal free fatty acid metabolism are closely related to ectopic lipid deposition. In this study, we investigate if inflammation tissue-specifically disrupts lipogenesis and lipolysis in nonadipose tissues and adipose tissue, resulting in ectopic lipid deposition in C57BL/6J mice.
We used casein injection in C57BL/6J mice to induce a chronic systemic inflammatory stress in vivo. Serum was analyzed for free fatty acid and cytokines. Insulin sensitivities were evaluated by glucose and insulin tolerance tests. Liver, muscle, adipose tissues were taken for lipid analysis. Real-time polymerase chain reaction and western blotting were used to examine the gene and protein expression of molecules involved in adipogenesis and lipolysis in tissues.
Casein injection elevated serum levels of IL-6 and SAA in mice, which are associated with increased lipid accumulation in liver and muscle, suggesting that chronic systemic inflammation induces ectopic lipid deposition in nonadipose tissues. The inflammatory stress upregulated mRNA and protein expression of sterol regulatory element binding protein 1, fatty acid synthase, and acetyl CoA carboxylase alpha, while inhibited these molecules expression in adipose. Interestingly, in the same experimental setting, inflammation increased triglyceride lipase and hormone-sensitive lipase expression in white adipose tissue. Inflammation also induced insulin resistance and increased serum free fatty acid levels in C57BL/6J mice.
Chronic systemic inflammation increased lipogenesis in nonadipose tissues and lipolysis in white adipose tissue, resulting in ectopic lipid deposition in nonadipose tissues. This disturbed free fatty acid homeostasis and caused insulin resistance in C57BL/6J mice.
Ectopic lipid deposition which is defined as excess lipids deposited in nonadipose tissues, mainly in liver and skeletal muscle, has been indicated to be a possible major culprit in development of insulin resistance and is rapidly becoming a world-wide public health problem because of the associated development of type 2 diabetes (T2DM), non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease . Using magnetic resonance spectroscopy, it has been demonstrated that increased intrahepatic lipid content is closely correlated to impaired hepatic insulin sensitivities in nondiabetic and diabetic individuals [2, 3]. Consistently, in T2DM patients, insulin requirements are closely related to their hepatic lipid content . Studies also found that an increase of intramyocellular lipid content, assessed by muscle biopsy or magnetic resonance/computed tomography, was positively correlated with the development of muscle insulin resistance and a better predictor of impaired insulin action than visceral adiposity , while a decrease in intramyocellular lipid content by weight loss improved insulin sensitivity [6, 7].
It has been demonstrated that in both patients and animal models, chronic systemic inflammation characterized by the increase of serum levels of C-reactive protein (CRP) and pro-inflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) is closely related the development of NAFLD, insulin resistance and other metabolic disorders . Furthermore, in vivo and in vitro studies have demonstrated that inflammatory cytokines increase serum free fatty acid (FFA) levels, causing dyslipidemia and NAFLD which can be prevented by using anti-cytokine antibodies in a mouse model [9, 10]. However, the effect of chronic systemic inflammation on FFA accumulation in liver and muscle as well as its underlying mechanisms remains unclear.
Increasing lipogenesis in nonadipose tissues play a crucial role in ectopic lipid deposition . In mammalian species, lipogenesis of cell is under control of a family of membrane-bound transcription factors designated sterol regulatory binding proteins (SREBPs). SREBPs are members of the basic helix-loophelix leucine zipper family of transcription factors [12, 13], which contain two transmembrane domains and localize in the endoplasmic reticulum (ER) as a precursor protein after synthesis. SREBPs on demand are escorted to the Golgi complex for two sequential cleavages by two proteases, by which the transcriptional active domains (NH2- terminal) enter the nucleus and bind to the cognate sterol-regulatory element (SRE) sites, activating transcription of target genes. Two forms of SREBPs have been characterized: SREBP1 and SREBP2. Specific analyses suggest SREBP1 may be selectively involved in activation of genes in free fatty acid metabolism. SREBP1 regulates the expression of genes encoding rate-limiting enzymes responsible for de novo lipogenesis, of which fatty acid synthase (FAS) and acetyl-CoA carboxylase alpha (ACCα) seems to be particularly important since their expressions are parallel to the changes of FFA synthesis rates.
FFA homeostasis of adipocytes is not only dependent on lipogenesis but also lipolysis. Both adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) can initiate triglyceride (TG) degradation by cleaving the first ester bond. Importantly, ATGL represents the rate-limiting lipolytic enzyme in mammals, and HSL, increased by insulin resistance is unique in its capacity to break down the second ester bond, converting diglycerides (DG) to monoglycerides in adipose tissue.
We and other groups demonstrated that chronic systemic inflammation causes cholesterol accumulation in liver, kidney and vessels by causing cholesterol redistribution and disrupting intracellular cholesterol homeostasis . The current study was undertaken to investigate if chronic systemic inflammation activated SREBP1, FAS and ACCα expression in liver and muscle, and increased ATGL and HSL expression in white adipose tissue, thereby causing ectopic lipid deposition as well as dyslipidemia and insulin resistance in C57BL/6J mice.
Animal care and experimental procedures were performed with approval from the Animal Care Committee of Chongqing Medical University. Eight week-old C57BL/6J mice were randomly assigned to receive a normal chow diet (NCD, n = 6) or NCD plus subcutaneous injection of 0.5 mL 10% casein (NCD+Casein, n = 6) or a high fat diet (15% fat, 1.25% cholesterol, 0.5% cholic acid) (HFD, n = 6) or HFD plus subcutaneous injection of 0.5 mL 10% casein (HFD+Casein, n = 6). Subcutaneous injection of 0.5 mL PBS was used as controls in the NCD and HFD groups. The injections were done every other day and the mice were culled 18 weeks after first injection. At termination, blood samples were taken for cytokines and lipid assays, and tissue samples were collected for further assessments.
Serum IL-6 (R&D, Minneapolis, USA) and serum amyloid A protein (SAA) concentrations were measured by ELISA kits. Intracellular TG concentrations were determined enzymatically with commercial kits (Jiancheng, Nanjing, China). FFA concentrations were determined calorimetrically using commercial kits (Applygen Technologies, Beijing, China).
Observation of Lipid Accumulation
The lipid accumulation in liver, muscle and white adipose tissue (epididymal fat pads) of C57BL/6J mice was evaluated by Oil Red O staining. Briefly, samples were fixed with 5% formalin solution and then stained with Oil Red O for 30 minutes. Finally, the samples were counterstained with hematoxylin for 5 minutes. Liver, muscle and white adipose tissue were fixed, dehydrated, infiltrated and embedded following routine method. Results were examined by light microscopy.
Quantitative Measurement of Intracellular TG and FFA
Quantitative measurements of TG and FFA were performed using commercial kits (Jiancheng, Nanjing, China and Applygen Technologies, Beijing, China). Briefly, samples were collected and lipids were extracted by addition of 1 mL solvents (TG: isopropanol/chloroform =2/3.5, FFA: chloroform/heptane/methanol = 5/5/1). The lipid phase was collected, dried in vacuum. The concentration of TG and FFA were analyzed using standards and normalized by total protein from tissues.
Glucose Tolerance Tests
Before each glucose tolerance tests, mice were starved overnight but allowed free access to water. The glucose tolerance was tested by the intraperitoneal injection of 2 mg D-glucose/g body weight (Sigma, St. Louis, US). The blood glucose and serum insulin concentrations were determined in blood, which were taken from the cut tail tip, before and 15, 30, 60, and 120 minutes after the administration of glucose. The glucose concentrations were determined using an ACCU-CHEK Advantage blood glucose meter (Roche, Mannheim, Germany).
Insulin Tolerance Tests
Before each insulin tolerance tests, mice were starved overnight but allowed free access to water. The insulin tolerance was tested by the intraperitoneal injection of 1 mU insulin/g body weight (Sigma, St. Louis, US). The glucose concentrations in blood were determined using an ACCU-CHEK Advantage blood glucose meter (Roche, Mannheim, Germany), which were taken from the cut tail tip, before and 15, 30, 60, and 120 minutes after the administration of insulin.
Real-time Reverse Transcription Polymerase Chain Reaction
Total RNA were isolated from liver, muscle and white adipose tissue homogenates from C57BL/6J mice using the guanidinium-phenol-chloroform method. Real-time reverse transcription polymerase chain reaction (PCR) was performed in a Bio-Rad Sequence Detection System (Hercules, US) using SYBR Green dye (Applied Biosystems Inc, Foster City, US) according to the manufacturer's protocol. All the primers (Sigma-Genosys, UK) were designed by Primer Express Software V2.0 (Applied Biosystems, UK) (Table 1). To normalize expression data, 18s rRNA was used as an internal control gene.
Cytoplasm and nuclear proteins were extracted from liver, muscle and white adipose tissue using commercial kits (Pierce, Rockford, US). Sample proteins were separated by Sodium dodecyl sulfate polyacrylamide gel electrophoresis in a Bio-Rad mini Protein apparatus, then were transferred to NC membranes (Amersham Bioscience, Piscatway, US). The membrane were blocked with blocking buffer, and incubated with primary antibodies (anti-SREBP1, anti-FAS, anti-ACCα , anti-ATGL, anti-HSL and anti-β-actin from Santa Cruz biotechnology, Inc., Santa Cruz, CA), followed by an incubation with horseradish peroxidase-labeled secondary antibodies. Finally, detection procedures were performed using ECL Advance Western Blotting Detection kit (Amersham Bioscience, Piscatway, US).
In all experiments, data were evaluated for statistical significance using one-way ANOVA analysis of variance followed by Q-test. A difference was considered significant if the P value was less than 0.05.
Effects of casein injection on the levels of pro-inflammatory cytokines
We induced a chronic systemic inflammation by subcutaneous injection of 10% casein in C57BL/6J mice. There were significant increases of SAA and IL-6 in casein-injected mice fed either NCD or HFD compared with the respective controls (Figure 1A and 1B), suggesting that chronic systemic inflammation was successfully induced in C57BL/6J mice.
Effects of chronic systemic inflammation on ectopic lipid deposition of C57BL/6J mice
Oil Red O staining showed that a HFD for 18 weeks induced lipid droplet accumulation in the liver (Figure 2A III vs. 2A I), muscle (Figure 2B III vs. 2B I), and white adipose tissues (Figure 2C III vs. 2C I) compared with NCD group of C57BL/6J mice. Chronic systemic inflammation induced by casein injection exacerbated lipid accumulation in the liver from mice fed with NCD (Figure 2A II vs. 2A I) and HFD (Figure 2A IV vs. 2A III) as evidenced by Oil Red O staining and increased the index of liver weight/body weight (Table 2). Chronic systemic inflammation also increased lipid accumulation in the muscle from mice fed with NCD and HFD, with the appearance of massive lipid vacuoles compare to the respective controls (Figure 2C II vs. 2C I and 2C IV vs. 2C III). Interestingly, lipid droplet accumulation has no obvious change in while adipose tissue in the casein-injected mice fed with NCD or HFD (Figure 2E, I-IV). Quantitative assay further demonstrated that casein injection increased TG and FFA levels in muscle, to a greater degree in liver, and has no effect on TG and FFA levels in white adipose tissue of C57BL/6J mice (Figure 2B, D and 2F).
Effects of inflammation stress on lipogenesis in all tissues and lipolysis gene expression in white adipose tissue of C57BL/6J mice
To investigate potential mechanisms of the ectopic lipid deposition, we evaluated the effects of chronic systemic inflammation on the gene and protein expression of SREBP1, FAS, ACCα in liver, muscle and white adipose tissue of the C57BL/6J mice.
Casein injection increased the mRNA (Figure 3A, B) and protein (Figure 4A, B) expression of SREBP1, FAS and ACCα in liver and muscle, especially in the mice fed with HFD, while it decreased mRNA and protein expression of these lipogenic molecules in white adipose tissue (Figure 3C and 4C). Interestingly, chronic systemic inflammation increased mRNA (Figure 3D) and protein (Figure 4D) expression of ATGL and HSL in white adipose tissue.
Effects of inflammation stress on the levels of glucose, insulin and lipid in the serum of C57BL/6J mice
Serum lipid assay demonstrated that levels of FFA in the casein-injected mice fed with NCD or HFD were increased compared with the respective controls (Figure 5A), suggesting that chronic systemic inflammation results in dyslipidemia in C57BL/6J mice. The fasting glucose levels in HFD plus casein injection group were increased compared to HFD alone group (Figure 5B). After glucose loading, blood glucose concentrations in HFD plus casein injection group were persistently higher than HFD group (Figure 5C), suggesting that chronic systemic inflammation induced glucose intolerance in C57BL/6J mice. After insulin challenge, blood glucose levels initially were decreased, but increased faster and higher in HFD plus casein injection group than in HFD group after 30 min, suggesting that chronic systemic inflammation decreased insulin sensitivity in C57BL/6J mice (Figure 5D).
Chronic systemic inflammation plays an important role in pathogenesis of multiple metabolic disorders, including insulin resistance, T2DM, NAFLD, atherosclerosis, obesity and dyslipidemia [15, 16]. In this study, we use subcutaneous injection of casein to induce chronic systemic inflammation in C57BL/6J mice fed with NCD or HFD to investigate if inflammation causes ectopic lipid deposition in nonadipose tissues. The casein injection model has been used in studies of atherosclerosis and liver steatosis . Compared to other sole cytokine-treated models, casein-injection induces multiple cytokines release which is more likely to mimic chronic systemic inflammatory states observed in patients with inflammatory diseases . It is well-accepted that both SAA and IL-6 are good inflammatory markers for systemic and hepatic inflammatory stress. Our results showed that casein injection significantly increased serum levels of SAA and IL-6, suggesting that chronic systemic inflammation was successfully induced in C57BL/6J mice.
Normally, FFA delivered to adipose tissue is converted to TG for storage during states of nutrient abundance. Therefore white adipose tissue has a unique capacity to store large amounts of excess lipid, while nonadipose tissues in which FFA was utilized have a limited capacity for storage of lipids [19, 20]. Adipose lipids also can be released into circulation to form albumin/FFA complexes, which allow FFA transport into nonadipose tissues, such as muscle, heart, kidney and liver for β oxidation on demand. Insulin regulates this process to maintain FFA homeostasis in balance. As liver and muscle are main insulin-sensitive and ectopic lipid accumulated tissues , we examined the effect of chronic systemic inflammation on lipid accumulation in these tissues. Oil Red O staining and quantitative assays demonstrated massive TG and FFA accumulation in the liver and muscle in casein-injected mice fed with NCD or HFD, suggesting a strong association between ectopic lipid deposition and chronic systemic inflammation. We also observed that the increases of TG and FFA contents induced by inflammation are more obvious in liver than in muscle in both NCD and HFD fed mice, which may attribute to the preferential ability of liver in a tissue-specific manner for lipogenesis. Interestingly, in the same experimental setting, chronic systemic inflammation has no obvious effects on the lipid contents in white adipose tissues.
Furthermore, we studied the expression of key molecules involved in lipogenesis to explore potential mechanisms of accelerated lipid accumulation induced by casein injection. Our results showed that chronic systemic inflammation up-regulated mRNA and protein expression of SREBP1, ACCα and FAS in liver and muscle, while decreasing the expression of these genes in adipose tissue. These data suggest that inflammation tissue-specifically switches on lipogenesis in nonadipose tissues, especially in liver while switches off lipogenesis in adipose tissue.
Lipid metabolism in adipose tissue is governed by lipogenesis and lipolysis. The lipolysis of white adipose tissue is complicated multi-step processes which performed from TG to glycerol and FFA. Previous studies discovered that enzyme ATGL seems to be responsible for the bulk of triacylglycerol hydrolase activity in various cells and ATGL has low affinity to diacylglycerides and monoacylglycerides. The major diacylglyceride lipase in adipocytes is HSL. Monoacylglyceride products of HSL are hydrolyzed by constitutively active monoacylglyceride lipase. We showed that casein injection increased both mRNA and protein expression of ATGL and HSL in white adipose tissue, suggesting that chronic systemic inflammation disrupts lipid metabolism by increasing lipolysis in addition to an impaired lipogenesis in adipose tissue.
Ectopic lipid deposition is closely related to the development of insulin resistance and dyslipidaemia . We evaluated serum lipids, insulin and glucose tolerance in the mice. Our data demonstrated that chronic systemic inflammation induced by casein injection exacerbated hyperlipidaemia in C57BL/6J mice. Accordingly, in this study, we also observed that casein injection induced hyperglycemia and insulin resistance in C57BL/6J mice. In this context, insulin cannot effectively suppress adipose tissue lipid hydrolysis which in turn increased adipose tissue lipolysis.
This study demonstrated that chronic systemic inflammation increased lipogenesis in nonadipose tissues, while it down-regulated lipogenesis and up-regulated lipolysis in white adipose tissues, resulting in ectopic lipid deposition in nonadipose tissues. The deposition of large amounts of lipids in nonadipose tissue may trigger ER stress, oxidative stress and apoptosis, thereby causing tissue injuries. The cytokines or chemokines released by injured cells further exacerbate inflammation, lipid accumulation and insulin resistance in a vicious cycle [23, 24]. The inflamed model established in the experiments may be useful for studying the organ cross-talks for FFA homeostasis and the mechanisms of ectopic lipid deposition induced by chronic systemic inflammation, especially rising from chronic inflammatory diseases characterized by an increased CRP level, as in Crohn's disease , autoimmune diseases , T2DM, and progressive NAFLD .
This study was supported by the National Natural Science Foundation of China (30871159, 30971389, 81070631, 81070317 and Key Program, No. 81030008), the Ministry of Education of China (20105503120004), Chongqing Education Committee (KJ110302), the Moorhead Trust, the Royal Free Hospital Special Trustees Grant-115.
Acetyl-CoA carboxylase alpha
Adipose triglyceride lipase
Fatty acid synthase
Free fatty acid
High fat diet
Non-alcoholic fatty liver disease
Normal chow diet
Polymerase chain reaction
Serum amyloid A protein
Sterol regulatory binding proteins
Sterol regulatory binding protein 1
Sterol regulatory binding protein 2
Type 2 diabetes
Tumor necrosis factor alpha
Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002, 23: 201-29. 10.1210/er.23.2.201
Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA: Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab. 2004, 89: 200-6. 10.1210/jc.2003-031315
Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab. 2002, 87: 3023-8. 10.1210/jc.87.7.3023
Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Järvinen H: Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes. 2000, 49: 749-58. 10.2337/diabetes.49.5.749
Pan DA, Lillioja S, Kriketos AD, Milner MR, Baur LA, Bogardus C, Jenkins AB, Storlien LH: Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes. 1997, 46: 983-8. 10.2337/diabetes.46.6.983
Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL: Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes. 1999, 48: 839-47. 10.2337/diabetes.48.4.839
Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE: Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes. 1997, 46: 1579-85. 10.2337/diabetes.46.10.1579
Greenfield JR, Campbell LV: Relationship between inflammation, insulin resistance and type 2 diabetes: 'cause or effect'?. Curr Diabetes Rev. 2006, 2: 195-211. 10.2174/157339906776818532
Marra F, Bertolani C: Adipokines in liver diseases. Hepatology. 2009, 50: 957-69. 10.1002/hep.23046
Grunfeld C, Feingold KR: The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy. 1991, 3: 143-58. 10.1007/BF02172087
Medina-Gomez G, Gray S, Vidal-Puig A: Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr. 2007, 10: 1132-7.
Eberle D, Hegarty B, Bossard P, Ferre P, Foufelle F: SREBP transcription factors: master regulators of lipid homeostasis. Biochimie. 2004, 86: 839-48. 10.1016/j.biochi.2004.09.018
Espenshade PJ, : sterol-regulated transcription factors. J Cell Sci. 2006, 119: 973-6. 10.1242/jcs02866
Ma KL, Ruan XZ, Powis SH, Chen Y, Moorhead JF, Varghese Z: Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice. Hepatology. 2008, 48: 770-81. 10.1002/hep.22423
Tarui S, Tokunaga K, Fujioka S, Matsuzawa Y: Visceral fat obesity: anthropological and pathophysiological aspects. Int J Obes. 1991, 15 (Suppl 2): 1-8.
Wellen KE, Hotamisligil GS: Inflammation, stress, and diabetes. J Clin Invest. 2005, 115: 1111-9.
Miura K, Takahashi Y, Shirasawa H: Immunohistochemical detection of serum amyloid A protein in the liver and the kidney after casein injection. Lab Invest. 1985, 53: 453-63.
Zhang H, Ching S, Chen Q, Li Q, An Y, Quan N: Localized inflammation in peripheral tissue signals the CNS for sickness response in the absence of interleukin-1 and cyclooxygenase-2 in the blood and brain. Neuroscience. 2008, 157: 895-907. 10.1016/j.neuroscience.2008.09.038
Manco M, Calvani M, Mingrone G: Effects of dietary fatty acids on insulin sensitivity and secretion. Diabetes Obes Metab. 2004, 6: 402-13. 10.1111/j.1462-8902.2004.00356.x
Yu YH, Ginsberg HN: Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res. 2005, 96: 1042-52. 10.1161/01.RES.0000165803.47776.38
Korenblat KM, Fabbrini E, Mohammed BS, Klein S: Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology. 2008, 134: 1369-75. 10.1053/j.gastro.2008.01.075
Pessin JE, Saltiel AR: Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest. 2000, 106: 165-9. 10.1172/JCI10582
Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001, 120: 1183-92. 10.1053/gast.2001.23256
Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE: Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008, 103: 1372-9. 10.1111/j.1572-0241.2007.01774.x
Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G: Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z Gastroenterol. 2006, 44: 245-8. 10.1055/s-2006-926502
Kahraman A, Miller M, Gieseler RK, Gerken G, Scolaro MJ, Canbay A: Non-alcoholic fatty liver disease in HIV-positive patients predisposes for acute-on-chronic liver failure: two cases. Eur J Gastroenterol Hepatol. 2006, 18: 101-5. 10.1097/00042737-200601000-00018
Clark JM, Diehl AM: Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002, 2: 210-5. 10.1007/s11892-002-0085-3
The authors declare that they have no competing interests.
MM and LZ carried out experiments, data collection, performed the statistical analysis and drafted the manuscript. QL participated in the coordination of the animal experiments. AIH , ZV , JFM, SHZ, SHP and QFL helped to draft the manuscript. YXC and XZR participated in the design of the experiments and helped to draft the manuscript. All authors read and approved the final manuscript.
Mei Mei, Lei Zhao contributed equally to this work.